Dynavax (DVAX) Tops Q3 EPS by 14c; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Dynavax Reports Third Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
November 2, 2023 4:01 PM EDTGenerated quarterly HEPLISAV-B® vaccine net product revenue of $62.3 million, a 66% year-over-year increaseRaising full year HEPLISAV-B net product revenue guidance to $210 - $220 million, compared to prior range of $200 - $215 millionCash and investments increased to $720 million at quarter end; expects positive free cash flow for full yearConference call today at 4:30 p.m. ET/1:30 p.m. PT
EMERYVILLE, Calif., Nov. 2, 2023 /PRNewswire/... More
